Of all CYP isoenzymes involved in safrole metabolism, CYP2A6 (the most active CYP isoenzyme in generation of the toxic safrole metabolite) and CYP2C9 (the main enzyme of the CYP2C subfamily in the hepatic tissue) are much more bioactive in patients with NAFLD [49,50], which might partially result in an increased associated risk of liver fibrosis. This evidence concerns the gene CYP2C9 and metabolic dysfunction-associated steatotic liver disease.